Inhibikase Therapeutics Operating Income Over Time
| IKT Stock | USD 3.20 0.01 0.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Inhibikase Therapeutics Performance and Inhibikase Therapeutics Correlation. Inhibikase |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase Therapeutics. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.014 | Quarterly Revenue Growth (1.00) | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Inhibikase Therapeutics is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Inhibikase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase Therapeutics' market value can be influenced by many factors that don't directly affect Inhibikase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Inhibikase Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (8.6 M) | (26.7 M) | (29.5 M) | (37.8 M) | (62.1 M) | (14.5 M) | (15.2 M) |
| DMAC | (603.4 K) | (6.7 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.3 M) | (2.5 M) | (4.5 M) | (6.8 M) | (11.6 M) | (12.7 M) | (13.6 M) | (14 M) | (21.3 M) | (20.2 M) |
| VALN | (1.4 M) | (4.5 M) | (12.8 M) | (20.9 M) | (23.8 M) | (19.9 M) | (42.6 M) | (4 M) | 6.3 M | 1.5 M | (55.1 M) | (61.4 M) | (113.4 M) | (82.1 M) | (78 M) |
| VANI | (16 M) | (16 M) | (16 M) | (18 M) | (21.2 M) | (20 M) | (33.2 M) | (28.6 M) | (35.2 M) | (30.6 M) | (9.2 M) | (13.3 M) | (21.2 M) | (27 M) | (28.3 M) |
| DNLI | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (87.4 M) | (90.1 M) | (46.4 M) | (213.2 M) | 62.7 M | (295.8 M) | (340.7 M) | (196.7 M) | (206.5 M) |
| DNTH | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (35.7 M) | (60 M) | (83 M) | (78.7 M) | (13.1 M) | (29.7 M) | (48.2 M) | (50.6 M) |
| DOMH | 200 K | (4.3 M) | (3.5 M) | (15.3 M) | (30.6 M) | (52 M) | (8.6 M) | (3.8 M) | (6.9 M) | (5.7 M) | (6.5 M) | (9.4 M) | (14.3 M) | (21.8 M) | (20.7 M) |
| VCEL | (10.5 M) | (29 M) | (33.8 M) | (21 M) | (23.5 M) | (16.7 M) | (19.2 M) | (15 M) | (3.9 M) | (11.3 M) | 667 K | (7.9 M) | (17.1 M) | (6.5 M) | (6.8 M) |
| VCNX | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (21.1 M) | (27.3 M) | (32 M) | (28.3 M) | (22.5 M) | (19.9 M) | (22.9 M) | (24 M) |
| VCYT | (15.3 M) | (15.3 M) | (18.9 M) | (23.2 M) | (29 M) | (33.5 M) | (28.8 M) | (26.5 M) | (22.2 M) | (15.1 M) | (35.4 M) | (81.9 M) | (41.1 M) | (85.8 M) | (81.5 M) |
Inhibikase Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Operating Income description
Operating Income is the amount of profit realized from Inhibikase Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Inhibikase Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Inhibikase Therapeutics | IKT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Georgia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.2
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.